Astrazeneca And 3 Other Stocks Have Very High Payout Ratio
Astrazeneca And 3 Other Stocks Have Very High Payout Ratio
(VIANEWS) – Nuveen Arizona Premium Income Municipal Fund (NAZ), WhiteHorse Finance (WHF), Astrazeneca (AZN) are the highest payout ratio stocks on this list.
（VIANEWS）— Nuveen亞利桑那州保費收益市政基金（NAZ）、WhiteHorse Finance（WHF）、阿斯利康（AZN）是該清單上股息率最高的股票。
We have congregated information about stocks with the highest payout ratio up to now. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.
我們已經收集了有關迄今爲止派息率最高的股票的信息。派息率本身並不能保證良好的投資，但它可以衡量是否支付股息以及公司選擇如何發行股息。
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
在調查潛在投資時，股息支付率是一個很好的統計數據，因此以下是一些派息率超過30％的股票。
1. Nuveen Arizona Premium Income Municipal Fund (NAZ)
1。Nuveen 亞利桑那州保費收入市政基金 (NAZ)
2000% Payout Ratio
2000% 派息率
Nuveen Arizona Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is managed by Nuveen Asset Management, LLC. It invests in the fixed income markets of Arizona. The fund invests in municipal securities and other related investments the income, exempt from regular federal and Arizona income taxes that are rated Baa or BBB or better and having an average maturity of 18.66 years. It employs fundamental analysis with bottom-up stock picking approach to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's (S&P) Arizona Municipal Bond Index and Standard & Poor's (S&P) National Municipal Bond Index. The fund was formerly known as Nuveen Arizona Premium Income Municipal Fund. Nuveen Arizona Quality Municipal Income Fund was formed on November 19, 1992 and is domiciled in the United States.
Nuveen亞利桑那州優質市政收益基金是由Nuveen Investments, Inc.推出的封閉式固定收益共同基金，該基金由Nuveen資產管理有限責任公司管理。它投資於亞利桑那州的固定收益市場。該基金將收入投資於市政證券和其他相關投資，免徵評級爲Baa或BBB或更高且平均到期日爲18.66年的常規聯邦和亞利桑那州所得稅。它採用基本面分析和自下而上的選股方法來創建其投資組合。該基金根據標準普爾（S&P）亞利桑那州市政債券指數和標準普爾（S&P）全國市政債券指數衡量其投資組合的表現。該基金前身爲Nuveen亞利桑那州保費收入市政基金。Nuveen 亞利桑那州優質市政收益基金成立於1992年11月19日，總部設在美國。
Earnings Per Share
每股收益
As for profitability, Nuveen Arizona Premium Income Municipal Fund has a trailing twelve months EPS of $-0.13.
至於盈利能力，Nuveen Arizona Premium Income 市政基金的每股收益爲-0.13美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -14.88%.
在過去的十二個月中，該公司的股本回報率爲負-14.88％，用於衡量企業相對於股東權益的盈利能力。
Volume
音量
Today's last reported volume for Nuveen Arizona Premium Income Municipal Fund is 134026 which is 440.34% above its average volume of 24804.
亞利桑那州Nuveen保費收益市政基金今天上次公佈的交易量爲134026個，比其平均交易量24804高出440.34％。
2. WhiteHorse Finance (WHF)
2。白馬金融 (WHF)
213.24% Payout Ratio
213.24% 派息率
WhiteHorse Finance, LLC is a business development company.
WhiteHorse Finance, LLC是一家業務開發公司。
Earnings Per Share
每股收益
As for profitability, WhiteHorse Finance has a trailing twelve months EPS of $0.68.
至於盈利能力，WhiteHorse Finance的每股收益爲0.68美元。
PE Ratio
市盈率
WhiteHorse Finance has a trailing twelve months price to earnings ratio of 18.44. Meaning, the purchaser of the share is investing $18.44 for every dollar of annual earnings.
WhiteHorse Finance過去十二個月的市盈率爲18.44。這意味着，該股票的購買者每1美元的年收益將投資18.44美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.74%.
在過去十二個月中，該公司的股本回報率爲4.74％，用於衡量企業相對於股東權益的盈利能力。
Sales Growth
銷售增長
WhiteHorse Finance's sales growth is negative 2.7% for the present quarter and negative 4.2% for the next.
WhiteHorse Finance本季度的銷售增長爲負2.7％，下一季度的銷售增長爲負4.2％。
Yearly Top and Bottom Value
年度最高值和最低值
WhiteHorse Finance's stock is valued at $12.54 at 10:23 EST, below its 52-week high of $13.88 and way higher than its 52-week low of $11.13.
美國東部標準時間10點23分，WhiteHorse Finance的股票估值爲12.54美元，低於其52周高點13.88美元，遠高於其52周低點11.13美元。
Dividend Yield
股息收益率
According to Morningstar, Inc., the next dividend payment is on Dec 18, 2023, the estimated forward annual dividend rate is 1.54 and the estimated forward annual dividend yield is 12.25%.
根據晨星公司的數據，下一次股息將在2023年12月18日支付，預計的遠期年股息率爲1.54，預計的遠期年度股息收益率爲12.25％。
3. Astrazeneca (AZN)
3.阿斯利康 (AZN)
76.72% Payout Ratio
76.72% 派息率
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC是一家生物製藥公司，專注於處方藥的發現、開發、製造和商業化。該公司上市的腫瘤產品包括Calquence、Enhertu、Faslodex、Imfinzi、Iressa、Koselugo、Lumoxiti、Lynparza、Orpathys、Tagrisso和Zoladex；用於腫瘤學的Andexxa/Ondexxya、Atacand HCT、Atacand HCT、Atacand Plus、Brilinta/Brilique、Bydureon/Byn 用於心血管、腎臟和新陳代謝疾病的 Evenzo、Farxiga/Forxiga、Komboglyze/Kombiglyze XR、Lokelma、Onglyza、Qtern、Xigduo/Xigduo 和 Zestril XR，用於心血管、腎臟和新陳代謝疾病；Accolate、Accoleit、Vanticon、Bevespi Aerosphere、Breztri Aerosphere、Breztri Aerosphere、Breztri Aerosphere、Breztri Aerosphere icanyl Respules and Turbuhaler、Dalisp/Daxas、DuaklirGenuair、Fasenra、Pulmicort、Rhinocort、Saphnelo、Symbicort 和 Tezspire 用於呼吸和免疫學；Kanuma、Soliris、Strensiq 和 Ultomiris 用於罕見疾病。其上市的產品還包括治療呼吸道合胞病毒的Synagis；治療流感的Fluenz Tetra/FluMist四價藥；以及用於covid-19的Vaxzevria和Evusheld。該公司通過在英國、歐洲其他地區、美洲、亞洲、非洲和大洋洲的分銷商和當地代表處爲初級保健和專科護理醫生提供服務。它與Neurimmune AG簽訂了合作協議，以開發和商業化 NI006；與Personalis, Inc簽訂了研究合作以評估新的潛在治療細胞應用；與Cholesgen（上海）有限公司合作推進高膽固醇血癥和相關代謝性疾病的研發，並與BioCity Biopharma合作評估一種用於治療晚期肝細胞癌的單克隆抗體以及與 Cellectis 簽訂的合作協議。該公司前身爲澤尼卡集團有限公司，並於1999年4月更名爲阿斯利康集團。阿斯利康公司成立於1992年，總部位於英國劍橋。
Earnings Per Share
每股收益
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.89.
至於盈利能力，阿斯利康的每股收益爲1.89美元。
PE Ratio
市盈率
Astrazeneca has a trailing twelve months price to earnings ratio of 35.01. Meaning, the purchaser of the share is investing $35.01 for every dollar of annual earnings.
阿斯利康過去十二個月的市盈率爲35.01。這意味着，該股票的購買者爲每1美元的年收益投資35.01美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.32%.
該公司的股本回報率爲16.32％，用於衡量企業相對於股東權益的盈利能力。
Yearly Top and Bottom Value
年度最高值和最低值
Astrazeneca's stock is valued at $66.17 at 10:23 EST, way under its 52-week high of $76.56 and higher than its 52-week low of $61.73.
美國東部標準時間10點23分，阿斯利康的股票估值爲66.17美元，遠低於其52周高點76.56美元，高於其52周低點61.73美元。
Earnings Before Interest, Taxes, Depreciation, and Amortization
利息、稅項、折舊和攤銷前的收益
Astrazeneca's EBITDA is 5.
阿斯利康的息稅折舊攤銷前利潤爲5。
Volume
音量
Today's last reported volume for Astrazeneca is 2364060 which is 58.43% below its average volume of 5687530.
阿斯利康今天公佈的交易量爲2364060，比其平均成交量5687530低58.43％。
Sales Growth
銷售增長
Astrazeneca's sales growth is 6.8% for the current quarter and 13.1% for the next.
阿斯利康本季度的銷售增長爲6.8％，下一季度的銷售增長13.1％。
4. Templeton Emerging Markets Fund (EMF)
4。鄧普頓新興市場基金（EMF）
39.36% Payout Ratio
39.36% 派息率
Templeton Emerging Markets Fund is a closed-ended equity mutual fund launched by Franklin Resources Inc. The fund is managed by Templeton Asset Management Ltd. It invests in the public equity markets of emerging market countries across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value stocks of companies. The fund employs fundamental analysis with a focus on such factors as long-term earnings, asset value, and cash flow potential to create its portfolio. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. Templeton Emerging Markets Fund was formed on February 26, 1987 and is domiciled in the United States.
鄧普頓新興市場基金是由富蘭克林資源公司發起的封閉式股票共同基金。該基金由鄧普頓資產管理有限公司管理。它投資於全球新興市場國家的公開股票市場。該基金旨在投資在多元化領域運營的公司的股票。它主要投資於公司的價值股。該基金採用基本面分析，重點關注長期收益、資產價值和現金流潛力等因素來創建其投資組合。它以摩根士丹利資本國際新興市場指數衡量其投資組合的表現。鄧普頓新興市場基金成立於1987年2月26日，總部設在美國。
Earnings Per Share
每股收益
As for profitability, Templeton Emerging Markets Fund has a trailing twelve months EPS of $1.03.
至於盈利能力，鄧普頓新興市場基金的每股收益爲1.03美元。
PE Ratio
市盈率
Templeton Emerging Markets Fund has a trailing twelve months price to earnings ratio of 11.15. Meaning, the purchaser of the share is investing $11.15 for every dollar of annual earnings.
鄧普頓新興市場基金過去十二個月的市盈率爲11.15。這意味着，該股票的購買者每1美元的年收益將投資11.15美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.44%.
該公司的股本回報率爲7.44％，用於衡量企業相對於股東權益的盈利能力。
Dividend Yield
股息收益率
According to Morningstar, Inc., the next dividend payment is on Dec 14, 2023, the estimated forward annual dividend rate is 0.73 and the estimated forward annual dividend yield is 6.33%.
根據晨星公司的數據，下一次股息將在2023年12月14日支付，預計的遠期年股息率爲0.73，預計的遠期年度股息收益率爲6.33％。
Yearly Top and Bottom Value
年度最高值和最低值
Templeton Emerging Markets Fund's stock is valued at $11.48 at 10:23 EST, way under its 52-week high of $13.19 and higher than its 52-week low of $10.58.
美國東部標準時間10點23分，鄧普頓新興市場基金的股票估值爲11.48美元，遠低於其52周高點13.19美元，高於其52周低點10.58美元。
Revenue Growth
收入增長
Year-on-year quarterly revenue growth grew by 56.1%, now sitting on 8.58M for the twelve trailing months.
季度收入同比增長了56.1％，在過去的十二個月中目前爲858萬英鎊。
Moving Average
移動平均線
Templeton Emerging Markets Fund's value is above its 50-day moving average of $11.40 and under its 200-day moving average of $11.61.
鄧普頓新興市場基金的價值高於其50天移動平均線11.40美元，低於其200天移動平均線11.61美元。
1. 1 (1)
1. 1 (1)
1% Payout Ratio
1% 的支付率
1
1
Earnings Per Share
每股收益
As for profitability, 1 has a trailing twelve months EPS of $1.
至於盈利能力，1的每股收益爲1美元。
PE Ratio
市盈率
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
1 過去十二個月的市盈率爲 1。這意味着，股票的購買者爲每1美元的年收益投資1美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.
在過去的十二個月中，該公司的股本回報率爲1％，用於衡量企業相對於股東權益的盈利能力。
Growth Estimates Quarters
增長估算季度
The company's growth estimates for the present quarter and the next is 1% and 1%, respectively.
該公司對本季度和下個季度的增長估計分別爲1％和1％。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1's stock is considered to be overbought (>=80).
根據隨機振盪指標（超買和超賣狀況的有用指標），1的股票被視爲超買（>=80）。
Revenue Growth
收入增長
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
季度收入同比增長了1％，在過去的十二個月中目前爲1。
Volume
音量
Today's last reported volume for 1 is 1 which is 1% above its average volume of 1.
今天上次報告的1交易量爲1，比其平均交易量1高出1％。